Saturday, 31 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

CABKA EUR 12W Stock Bearish By 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of CABKA EUR 12W (AEX-Index: DSCW2.AS) dropped by a staggering 17.81% in 5 sessions from €0.07 to €0.06 at 02:08 EST on Monday, after five successive sessions in a row of losses. AEX-Index is rising 0.11% to €761.40, after two successive sessions in a row of gains.

CABKA EUR 12W's last close was €0.06, 17.81% below its 52-week high of €0.07.

About CABKA EUR 12W

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CABKA EUR 12W's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

CABKA EUR 12W's stock is valued at €0.06 at 02:08 EST, way below its 52-week low of €0.07.

More news about CABKA EUR 12W (DSCW2.AS).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowCABKA EUR 12WStock Price DownStock Market NowMarket SessionDSCW2.ASStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com